ATAI Life Sciences Files 8-K Report
Ticker: ATAI · Form: 8-K · Filed: Sep 29, 2025 · CIK: 1840904
| Field | Detail |
|---|---|
| Company | Atai Life Sciences N.V. (ATAI) |
| Form Type | 8-K |
| Filed Date | Sep 29, 2025 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k
TL;DR
ATAI Life Sciences filed an 8-K on 9/29/25. Standard disclosure.
AI Summary
On September 29, 2025, ATAI Life Sciences N.V. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific financial figures or significant business events were detailed in the provided excerpt.
Why It Matters
This filing indicates a routine update or disclosure from ATAI Life Sciences N.V. to the SEC, which may contain important information for investors.
Risk Assessment
Risk Level: low — The provided excerpt is a standard SEC filing notification without specific material events or financial disclosures that would indicate immediate risk.
Key Players & Entities
- ATAI Life Sciences N.V. (company) — Registrant
- September 29, 2025 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing for ATAI Life Sciences N.V.?
The filing is for "Other Events" and "Financial Statements and Exhibits" as of September 29, 2025.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is September 29, 2025.
What is the principal executive office address for ATAI Life Sciences N.V.?
The address is Prof. J.H. Bavincklaan 7, 1183 AT Amstelveen, The Netherlands.
What is the telephone number listed for ATAI Life Sciences N.V.?
The telephone number is +31 20 793 2536.
What is the SIC code for ATAI Life Sciences N.V.?
The Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 1,231 words · 5 min read · ~4 pages · Grade level 13.2 · Accepted 2025-09-29 17:07:57
Filing Documents
- ny20050228x7_8k.htm (8-K) — 35KB
- ny20050228x7_ex23-1.htm (EX-23.1) — 2KB
- ny20050228x7_ex99-1.htm (EX-99.1) — 1312KB
- ny20050228x7_ex99-2.htm (EX-99.2) — 1149KB
- 0001140361-25-036537.txt ( ) — 2785KB
- atai-20250929.xsd (EX-101.SCH) — 4KB
- atai-20250929_lab.xml (EX-101.LAB) — 22KB
- atai-20250929_pre.xml (EX-101.PRE) — 16KB
- ny20050228x7_8k_htm.xml (XML) — 4KB
01
Item 8.01. Other Events. This Current Report on Form 8-K is being filed to provide additional information related to Beckley Psytech Limited, a company incorporated in England and Wales ("Beckley Psytech"), in connection with the previously announced share purchase agreement, dated June 2, 2025 (the "SPA"), by and among ATAI Life Sciences N.V., a Dutch public company with limited liability ("atai" or the "Company"), Beckley Psytech and certain other parties thereto, pursuant to which atai agreed to acquire from the shareholders of Beckley Psytech, excluding atai, the entire issued share capital of Beckley Psytech not already owned by atai (the "Transaction"). The audited consolidated financial statements of Beckley Psytech Limited as of December 31, 2024 and December 31, 2023 and for each of the three years in the period ended December 31, 2024 are attached hereto as Exhibit 99.1 and incorporated herein by reference. The unaudited pro forma condensed combined financial information of atai giving effect to the Transaction, as well as certain other related transactions described therein, as of and for the six months ended June 30, 2025 and for the year ended December 31, 2024 (the "Unaudited Pro Forma Information") are attached hereto as Exhibit 99.2 and incorporated herein by reference. The Unaudited Pro Forma Information included in this Form 8-K is presented for illustrative purposes only and is not necessarily indicative of what atai's actual financial condition or results of operations would have been had such transactions been completed on the dates indicated. The Transaction is currently expected to close in the fourth quarter of 2025, subject to approval by atai's shareholders and satisfaction of other customary closing conditions. No assurance can be given that the Transaction will be consummated within this timeframe or at all. Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements with
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 23.1 Consent of PricewaterhouseCoopers LLP, independent auditors. 99.1 Audited financial statements of Beckley Psytech Limited as of December 31, 2024 and December 31, 2023 and for each of the three years in the period ended December 31, 2024. 99.2 Unaudited pro forma condensed combined financial information of atai giving effect to the Transaction, as well as certain other related transactions described therein, as of and for the six months ended June 30, 2025 and for the year ended December 31, 2024. 104 Cover Page Interactive Data File (embedded within the inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ATAI LIFE SCIENCES N.V. Date: September 29, 2025 By: /s/ Srinivas Rao Name: Srinivas Rao Title: Chief Executive Officer